MedChunk
Medically reviewed

JAK Inhibitors vs Traditional Alopecia Areata Treatment

Compare JAK inhibitors vs traditional alopecia areata treatments, including hair regrowth, side effects, treatment duration, safety, and who may benefit.

By Caleb Bennett Reviewed by Dr. Irene Medical review dateNov 19, 2026 16 min read

JAK inhibitors are newer medicines that can help people with severe alopecia areata regrow hair, while traditional treatments such as steroid injections and creams are often used for smaller patches of hair loss. JAK inhibitors target specific immune signals involved in hair loss, whereas older treatments work in different ways to control inflammation or support hair growth. The best choice depends on how much hair is affected, age, medical history, treatment risks, and personal preferences.

How Do JAK Inhibitors Differ From Traditional Alopecia Areata Treatments?

Alopecia areata is an autoimmune condition in which the immune system mistakenly attacks hair follicles. This disrupts normal hair growth and can cause round patches of hair loss or more extensive loss across the scalp and body.

Both JAK inhibitors and traditional treatments aim to improve hair growth, but they differ in how they work, how they are given, and which patients may benefit most.

According to the National Alopecia Areata Foundation, JAK inhibitors interfere with immune signals involved in attacks on hair follicles. Blocking these signals can allow the normal hair growth cycle to resume.

Traditional treatments include corticosteroid injections, steroid creams, minoxidil, topical immunotherapy, and certain medicines that suppress immune activity throughout the body. These treatments have been used for many years, although their effectiveness varies depending on the extent and pattern of hair loss.

JAK Inhibitors vs Traditional Treatments: Key Differences

Feature JAK Inhibitors Traditional Treatments
How they work Block specific immune signaling pathways linked to hair follicle inflammation Reduce inflammation, alter immune activity, or support hair growth
Common forms Oral tablets or capsules for approved alopecia areata treatments Injections, creams, solutions, and oral medicines
Typical use Severe or extensive alopecia areata Often used for limited hair loss; some options are used for more extensive disease
Clinical evidence Large clinical trials support several approved oral treatments for severe disease Evidence varies substantially between individual treatments
Treatment duration Often requires ongoing treatment to maintain regrowth May involve repeated sessions, courses of treatment, or ongoing use
Safety monitoring Requires screening, blood tests, and continued medical monitoring Depends on the treatment; local treatments generally need less systemic monitoring
Access and cost Can be expensive and may involve insurance restrictions Some established treatments are less costly, although access varies

Which JAK Inhibitors Are Used for Alopecia Areata?

Janus kinase inhibitors, usually called JAK inhibitors, are medicines that block enzymes involved in sending immune signals between cells. In alopecia areata, reducing these signals may help prevent immune activity from interfering with hair growth.

Several oral JAK inhibitors have received approval from the US Food and Drug Administration (FDA) for severe alopecia areata.

Baricitinib (Olumiant)

Baricitinib is an oral JAK inhibitor used to treat adults with severe alopecia areata. It is taken once daily and can help some patients regrow scalp hair, eyebrows, and eyelashes.

Results are gradual, and not everyone experiences substantial regrowth. Treatment response is generally assessed over several months.

Ritlecitinib (Litfulo)

Ritlecitinib is an oral treatment approved in the United States for people aged 12 years and older with severe alopecia areata.

It blocks specific enzymes involved in immune signaling and is taken once daily. Its approval provides an important systemic treatment option for eligible adolescents as well as adults.

Deuruxolitinib (Leqselvi)

Deuruxolitinib is another oral JAK inhibitor approved in the United States for adults with severe alopecia areata. It is taken twice daily.

Its use requires careful review of medical history, possible medication interactions, and appropriate safety testing.

The American Academy of Dermatology describes clinical trial results for these medicines. In separate trials, a meaningful proportion of patients achieved substantial scalp hair regrowth, although results differed by medication, treatment duration, and study design.

These trial results should not be interpreted as proof that one JAK inhibitor is better than another. Direct comparisons between individual medicines remain limited.

What Traditional Treatments Are Still Used for Alopecia Areata?

Traditional treatments remain useful, particularly when alopecia areata affects a limited area or when oral JAK inhibitors are unsuitable.

Corticosteroid Injections

Dermatologists commonly use corticosteroid injections, such as triamcinolone, for individual patches of hair loss.

The medicine is injected directly into affected skin to reduce local inflammation. Treatment may be repeated at intervals if the dermatologist considers it appropriate.

This approach can be effective for limited patches, but injecting many areas may be impractical when hair loss is widespread.

Possible side effects include discomfort during injections and temporary thinning or indentation of the skin at treated sites.

Topical Corticosteroids

Steroid creams, lotions, solutions, and foams can be applied to affected areas of the scalp.

They are frequently considered for children and people who prefer to avoid injections. The strength of the medicine and length of treatment depend on the patient's age, affected area, and clinical response.

Prolonged or inappropriate use of strong topical steroids can cause skin thinning and other local side effects.

Minoxidil

Minoxidil is a hair-growth medicine that may be used alongside treatments aimed at controlling alopecia areata.

It does not directly correct the autoimmune process responsible for the condition. Instead, it may help support hair growth in selected patients.

Topical minoxidil may cause scalp irritation or unwanted hair growth outside the intended treatment area. Oral minoxidil is sometimes prescribed off-label and requires additional assessment because it can affect blood pressure and cause other systemic effects.

Topical Immunotherapy

Topical immunotherapy involves applying a substance that produces a controlled allergic reaction on the scalp. Dermatologists may consider this approach for more extensive alopecia areata.

It requires repeated treatment sessions and specialist supervision. Possible reactions include itching, redness, swelling, and skin irritation.

Oral Corticosteroids and Other Immune-Suppressing Medicines

Oral corticosteroids may be used for rapidly progressing or extensive alopecia areata in selected patients. However, prolonged use is limited by side effects and the possibility of hair loss returning after treatment ends.

Medicines such as methotrexate and cyclosporine have also been used in some settings. Their benefits, safety concerns, and supporting evidence differ, so they are not direct substitutes for approved JAK inhibitors.

The American Academy of Dermatology outlines these established treatments and explains why dermatologists select different approaches according to the patient's hair loss, age, and health.

Are JAK Inhibitors More Effective Than Traditional Treatments?

JAK inhibitors have stronger clinical trial evidence for substantial hair regrowth in severe alopecia areata than many older systemic treatments. However, this does not mean they are the most appropriate treatment for every patient.

For a person with only a few small patches of hair loss, corticosteroid injections or topical treatment may provide a suitable approach without the risks and monitoring associated with an oral immune-modifying medicine.

For widespread scalp hair loss, repeated local injections may be less practical, and traditional treatments may not provide adequate improvement.

What Do Clinical Trials Show?

Clinical trials of approved JAK inhibitors have demonstrated that some patients with severe alopecia areata can regain substantial scalp hair coverage.

For example, studies of baricitinib have shown meaningful hair regrowth in approximately one-third of patients receiving certain studied doses. Trials of ritlecitinib and deuruxolitinib have also shown substantial regrowth in a proportion of treated patients.

These figures come from different studies with different treatment periods and patient populations. They should not be used to rank the drugs directly.

Traditional corticosteroid injections can also produce useful regrowth, especially in localized disease. However, comparing injection results in people with limited hair loss against oral drug results in people with extensive hair loss would not provide a fair measure of relative effectiveness.

Why Treatment Results Are Not Always Predictable

Response to treatment may depend on several clinical factors, including the extent of hair loss, its duration, the pattern of disease activity, previous treatment responses, and other health conditions.

Spontaneous regrowth can also occur, particularly in less extensive alopecia areata. This can make it difficult to judge whether a treatment caused every observed improvement.

Dermatologists may use scalp examinations, photographs, and standardized hair-loss measurements to assess progress over time.

JAK Inhibitors vs Steroids: Which Has More Side Effects?

Both treatments can cause side effects, but their safety concerns are different.

Local steroid injections and topical creams mainly produce side effects in the areas where they are used. Oral corticosteroids can affect the whole body, particularly with repeated or prolonged treatment.

Oral JAK inhibitors affect immune signaling throughout the body. This creates a need for screening and ongoing monitoring.

Possible Side Effects of JAK Inhibitors

Examples of less serious side effects reported with oral JAK inhibitor treatment include:

  • Headache
  • Nausea
  • Acne
  • Upper respiratory infections
  • Changes in laboratory test results

More serious potential risks include significant infections, blood clots, certain cardiovascular events, and malignancy. The FDA requires boxed safety warnings for approved oral JAK inhibitors, although the level of risk for an individual patient depends on the medicine and their health history.

Patients may need screening for infections such as tuberculosis, blood counts, liver tests, and other investigations before or during treatment. Vaccination history and possible drug interactions are also considered.

Possible Side Effects of Traditional Treatments

Different established treatments carry different risks:

  • Injected corticosteroids: Local skin thinning, indentations, and injection discomfort.
  • Topical corticosteroids: Skin thinning and irritation, particularly with inappropriate prolonged use.
  • Oral corticosteroids: Blood pressure changes, blood sugar changes, sleep disturbance, and bone-related complications with longer-term use.
  • Topical minoxidil: Scalp irritation and unwanted hair growth.
  • Topical immunotherapy: Allergic skin reactions and irritation.

A treatment with fewer systemic effects is not automatically better. The decision involves balancing the likelihood of meaningful hair regrowth against the risks of the specific treatment.

How Long Does Hair Regrowth Take With Each Treatment?

Hair regrowth usually takes time, regardless of the treatment chosen. The first visible changes may be small, and continued treatment or follow-up may be needed before the response can be assessed reliably.

With JAK Inhibitors

Some people notice hair regrowth during the first several months. Others require a longer period before a meaningful response is apparent.

For adults with severe alopecia areata, the National Alopecia Areata Foundation's treatment recommendations describe an initial treatment assessment period of approximately 6 to 12 months for oral JAK inhibitors.

If the medicine is helping, ongoing treatment is often recommended. Stopping therapy may lead to renewed hair loss.

With Traditional Treatments

Local corticosteroid treatment may produce visible improvement over several weeks to months in responsive patches.

Minoxidil and topical immunotherapy may also require months of consistent treatment before their effects can be evaluated.

Because alopecia areata can relapse, successful regrowth with any treatment does not guarantee permanent hair retention.

Can JAK Inhibitors and Traditional Treatments Be Used Together?

Yes. Dermatologists sometimes combine a JAK inhibitor with an established treatment when there is a specific reason to support additional hair growth.

For example, a patient receiving an oral JAK inhibitor may also be prescribed minoxidil or localized corticosteroid injections.

Combination treatment is not automatically more effective for everyone. The potential benefits, medication interactions, and added adverse effects must be considered.

Using more than one treatment that affects immune function requires particular care. Patients should not independently add oral steroids, immune-suppressing medicines, or another JAK inhibitor to a prescribed regimen.

Who May Benefit More From JAK Inhibitors?

Oral JAK inhibitors are particularly relevant for patients with severe alopecia areata, including some people with extensive scalp hair loss or significant eyebrow and eyelash involvement.

They may also be considered when the disease has a substantial effect on daily life and the expected benefits justify the treatment risks.

In September 2026, a US expert consensus statement published in JAMA Dermatology recommended FDA-approved oral JAK inhibitors as first-line, long-term treatment for adults with severe alopecia areata.

This recommendation does not mean that everyone with alopecia areata should take a JAK inhibitor. It specifically addresses adults with severe disease and does not automatically extend to people with limited hair loss, pregnant patients, or children.

When Traditional Treatment May Be Preferred

Established treatments may be more appropriate when hair loss affects only a few small areas, systemic medication risks outweigh potential benefits, or a person prefers local treatment.

Some patients may also need alternatives because of existing infections, medication interactions, pregnancy considerations, or other medical conditions.

What About Children and Teenagers?

Age is an important part of treatment selection.

Topical corticosteroids are commonly considered for younger children. Corticosteroid injections may be considered for selected older children or teenagers, depending on tolerance and clinical circumstances.

Ritlecitinib is FDA-approved for severe alopecia areata in people aged 12 years and older. Other oral JAK inhibitors have different age restrictions, and approvals can vary between countries.

Young patients need age-appropriate assessment, including discussion of safety, treatment burden, and the impact of hair loss on emotional well-being.

Cost and Access: Are JAK Inhibitors Worth Considering?

Cost can be a major difference between newer and traditional alopecia areata treatments.

Oral JAK inhibitors are prescription medicines that may be expensive, particularly when long-term use is needed. Insurance plans may require prior authorization or documentation of disease severity.

Some traditional treatments, including corticosteroid creams and injections, may be less expensive. However, repeated appointments, specialist procedures, and prolonged treatment can increase their overall cost.

The availability of individual JAK inhibitors and their approved indications also varies by country. US FDA approval does not necessarily mean that a medicine is approved, marketed, or reimbursed elsewhere.

Before starting treatment, patients can ask their dermatologist about expected duration, follow-up expenses, laboratory monitoring, and possible assistance programs.

How Do Dermatologists Decide Between JAK Inhibitors and Older Treatments?

Treatment selection involves more than measuring how much hair is missing.

A dermatologist usually reviews the history and pattern of hair loss, examines the scalp and affected areas, and considers previous treatment responses.

Other relevant considerations include:

  • Extent of scalp, eyebrow, eyelash, or body hair loss
  • How quickly the condition is progressing
  • Age and other medical conditions
  • History of infections, blood clots, or cardiovascular disease
  • Current medications and possible interactions
  • Pregnancy or plans for pregnancy
  • Personal treatment goals and tolerance for monitoring
  • Medication availability, cost, and insurance coverage

When oral JAK inhibitor treatment is being considered, additional screening and laboratory tests may be needed.

Patients who have persistent or increasing hair loss, difficulty managing treatment, or significant emotional distress should discuss these concerns with a dermatologist rather than changing medicines independently.

What Is the Best Overall Treatment Approach?

There is no single best treatment for every person with alopecia areata.

For limited patches, steroid injections or topical treatments may be reasonable first options. For adults with severe disease, approved oral JAK inhibitors now have an important role as primary treatment because they offer evidence-based potential for substantial hair regrowth.

Traditional treatments still have value, including as additional therapies alongside JAK inhibitors in selected cases.

The most useful treatment plan is one that addresses the extent and impact of hair loss while keeping medication risks, monitoring needs, affordability, and personal goals in view. A dermatologist can help compare these options and reassess the plan as the response becomes clearer.

Frequently Asked Questions

Common questions about choosing between JAK inhibitors and traditional alopecia areata treatments.

Are JAK inhibitors better than steroid injections for alopecia areata?

JAK inhibitors may be more suitable for severe or widespread alopecia areata, while steroid injections are often useful for a few small patches. There is not enough direct comparative evidence to say that JAK inhibitors are always better. The choice depends on the extent of hair loss, medical risks, and treatment goals.

Will hair fall out again after stopping JAK inhibitors?

Hair loss can return after JAK inhibitor treatment is stopped. These medicines help control immune activity associated with alopecia areata but do not provide a guaranteed permanent cure. Patients who respond well may need ongoing treatment, depending on their dermatologist's assessment.

Can someone take JAK inhibitors if minoxidil or steroids did not work?

Yes, some patients with severe alopecia areata may be candidates for oral JAK inhibitors after an inadequate response to established treatments. Previous treatment failure is not always required, particularly for adults with severe disease under current US expert recommendations. Eligibility depends on the medicine, medical history, and local prescribing rules.

Are JAK inhibitors safe to take for several years?

Long-term JAK inhibitor treatment may be appropriate for selected patients who benefit from it. However, these medicines carry important safety warnings, including risks involving infections, blood clots, and cardiovascular events. Continued treatment requires medical review and appropriate monitoring, and long-term risk varies between patients.

Do JAK inhibitors work for alopecia totalis and alopecia universalis?

They may help some people with alopecia totalis, which involves complete scalp hair loss, or alopecia universalis, which involves widespread body hair loss. Both are extensive forms of alopecia areata. Some patients achieve significant regrowth with oral JAK inhibitors, but a complete response is not guaranteed. A dermatologist can explain realistic treatment expectations.

Citations

  1. National Alopecia Areata Foundation — Available Treatments
  2. American Academy of Dermatology — JAK Inhibitors: What Your Dermatologist Wants You to Know
  3. American Academy of Dermatology — Alopecia Areata: Diagnosis and Treatment
  4. National Alopecia Areata Foundation — New US Treatment Recommendations for Severe Alopecia Areata in Adults
  5. JAMA Dermatology — Delphi Consensus Statement on Treatment of Severe Alopecia Areata in US Adults
Share this article